Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial DRUG C25003

Title
A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
Principal Investigator
Adam M Petrich
Details
  • Status: Accepting New Patients
  • Study Type: Therapeutic, Treatment
  • Protocol No:.DRUG C25003
Purpose
The main purpose of this study is to measure how well standard treatment plus brentuximab vedotin works compared with a standard treatment alone for Hodgkin lymphoma.
Overview
This study includes an investigational drug called brentuximab vedotin (also known as ADCETRIS®). ADCETRIS targets CD30, a protein on the surface of certain cells (a “marker”) that is found on some types of cancers such as Hodgkin lymphoma (HL). ADCETRIS targets CD30 on the cancer cell surface and may cause the cancer cells to die. ADCETRIS has been approved in the United States by the Food and Drug Administration (FDA) for treatment of some types of lymphoma in patients where other therapies have failed. The use of ADCETRIS in this study is experimental (investigational), which means that the drug has not been approved by the FDA for use in patients who have not received any prior treatment for their HL (also known as frontline therapy).
Eligibility
Some of the eligibility criteria include:
  • Participants must have a diagnosis of Hodgkin lymphoma and may not have had prior treatment for their cancer.
  • Participants must be 18 or older.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
Study participants will be randomly assigned (like flipping a coin) to one of two groups of treatment (Arm A or Arm B). Half of the patients will be assigned to Arm A and the other half of the patients will be assigned to Arm B. Arm A includes ADCETRIS, in combination with drugs that are commonly used for frontline therapy, while Arm B is a commonly prescribed frontline therapy regimen that does not contain ADCETRIS.
Contact
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
312.695.1102
cancertrials@northwestern.edu

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Adam M Petrich

last updated: 21-Sep-14 11:11 PM

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.